Healthcare · NIFTY 50
Cipla Limited
NSECIPLA
BSE500087 ISININE059A01026 SeriesEQ Listed on NSE · BSE
₹1,408.30 -11.60 (-0.82%) Updated 12 Nov, 6:47 pm IST
Price, daily close-6.14% in a year
Today
- Open
- ₹1,413.60
- Prev close
- ₹1,419.90
- Day high
- ₹1,420.00
- Day low
- ₹1,399.50
- Volume
- 16.84 L
- Value traded
- ₹236.64 Cr
- Upper circuit
- ₹1,446.50
- Lower circuit
- ₹1,362.30
- 52W high
- ₹1,539.70
- 52W low
- ₹1,165.70
- 1 month
- +7.97%
- 6 months
- +8.13%
52W low52W high
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Market cap₹113,770 Cr
P/E (TTM)39.31
P/B3.21
Book value / share₹438.14
EPS (TTM)₹35.83
ROE8.2%
Dividend yield0.92%
Dividend (12m)₹13.00 / share
Net margin (TTM)10.3%
Operating margin18.7%
Debt / equity0.01
Current ratio3.59
EV / EBITDA24.89
Sales growth (YoY qtr)-2.44%
Profit growth (YoY qtr)-35.05%
Sales CAGR 3Y+7.37%
Profit CAGR 3Y+11.45%
Shares80.79 Cr
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Revenue · QoQ (vs last quarter)
—-6.7%+8.6%+5.3%+0.3%-4.9%+3.4%+9.1%-6.8%-7.5%+8.8%+4.0%
Revenue · YoY (vs a year ago)
————+7.1%+9.2%+3.9%+7.6%+0.0%-2.8%+2.3%-2.4%
Net profit · QoQ (vs last quarter)
—-11%+25%+11%+21%-22%+6.2%+4.1%-50%-18%+42%+11%
Net profit · YoY (vs a year ago)
————+49%+30%+10%+3.7%-57%-55%-39%-35%
RevenueNet profitLine = trend
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
EPS (₹) · YoY (vs a year ago)
————+49%+30%+10%+3.7%-57%-55%-39%-35%
EPS (₹)Line = trend
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,604 | 6,163 | 6,694 | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 | 7,404 |
| Other income | 185 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | 206 | 148 | 211 | 151 |
| Total income | 6,788 | 6,413 | 6,854 | 7,242 | 7,295 | 7,019 | 7,216 | 7,858 | 7,281 | 6,689 | 7,330 | 7,555 |
| Raw material | 1,196 | 1,253 | 1,241 | 1,474 | 1,297 | 1,398 | 1,469 | 1,528 | 1,462 | 1,382 | 1,357 | 1,524 |
| Purchases | 927 | 739 | 1,100 | 815 | 913 | 1,024 | 1,025 | 893 | 1,249 | 1,285 | 1,252 | 1,313 |
| Employee cost | 1,068 | 1,084 | 1,194 | 1,208 | 1,198 | 1,233 | 1,312 | 1,315 | 1,325 | 1,414 | 1,497 | 1,475 |
| Other expenses | 1,569 | 1,713 | 1,591 | 1,675 | 1,622 | 1,770 | 1,696 | 1,882 | 1,862 | 1,923 | 1,762 | 1,908 |
| Total expenses | 5,120 | 5,153 | 5,243 | 5,453 | 5,378 | 5,515 | 5,446 | 6,005 | 6,112 | 5,982 | 6,248 | 6,378 |
| Operating profit | 1,553 | 1,316 | 1,716 | 1,886 | 1,989 | 1,538 | 1,778 | 1,895 | 979 | 955 | 1,192 | 1,388 |
| OPM % | 23.5% | 21.4% | 25.6% | 26.7% | 28.1% | 22.8% | 25.6% | 25.0% | 13.8% | 14.6% | 16.7% | 18.7% |
| Finance cost | 30.1 | 17.6 | 18.0 | 15.4 | 14.6 | 14.0 | 14.1 | 13.2 | 14.0 | 13.1 | 17.0 | 16.7 |
| Depreciation | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 | 345 |
| Exceptional items | -195 | — | — | — | — | — | — | — | -276 | — | — | — |
| Profit before tax | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 | 1,177 |
| Tax | 405 | 325 | 435 | 483 | 332 | 279 | 478 | 500 | 219 | 157 | 295 | 321 |
| Net profit | 1,068 | 932 | 1,175 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 | 852 |
| Profit to shareholders | 1,056 | 939 | 1,178 | 1,303 | 1,571 | 1,222 | 1,298 | 1,351 | 676 | 555 | 789 | 878 |
| EPS (₹) | 13.07 | 11.62 | 14.57 | 16.12 | 19.43 | 15.12 | 16.06 | 16.72 | 8.36 | 6.86 | 9.76 | 10.85 |
Profit & loss
Results for each year
8 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue · YoY (vs a year ago)
—+4.7%+12%+14%+4.5%+13%+6.9%+2.2%
Net profit · YoY (vs a year ago)
—+1.2%+56%+4.7%+11%+47%+28%-26%
RevenueOperating profitNet profitLine = trend
| ₹ Cr | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 |
| Other income | 477 | 344 | 266 | 281 | 475 | 747 | 862 | 882 |
| Total expenses | 14,760 | 15,298 | 16,136 | 18,369 | 19,008 | 20,624 | 21,589 | 23,545 |
| Employee cost | 2,857 | 3,027 | 3,252 | 3,530 | 3,830 | 4,310 | 4,833 | 5,366 |
| Operating profit | 3,097 | 3,206 | 4,252 | 4,371 | 4,845 | 6,096 | 7,128 | 5,607 |
| OPM % | 18.9% | 18.7% | 22.2% | 20.1% | 21.3% | 23.7% | 25.9% | 19.9% |
| Finance cost | 168 | 197 | 161 | 106 | 110 | 89.9 | 62.0 | 54.4 |
| Depreciation | 1,326 | 1,175 | 1,068 | 1,052 | 1,172 | 1,051 | 1,107 | 1,211 |
| Profit before tax | 2,079 | 2,178 | 3,290 | 3,493 | 4,038 | 5,702 | 6,821 | 5,224 |
| Tax | 570 | 631 | 889 | 934 | 1,203 | 1,547 | 1,530 | 1,354 |
| Tax rate % | 27.4% | 29.0% | 27.0% | 26.7% | 29.8% | 27.1% | 22.4% | 25.9% |
| Net profit | 1,492 | 1,500 | 2,389 | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 |
| Profit to shareholders | 1,528 | 1,547 | 2,405 | 2,517 | 2,802 | 4,122 | 5,273 | 3,879 |
| Net margin % | 9.3% | 9.0% | 12.6% | 11.6% | 12.3% | 16.0% | 19.1% | 13.8% |
| EPS (₹) | 18.93 | 19.16 | 29.79 | 31.17 | 34.69 | 51.01 | 65.24 | 48.00 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Mar 23
Mar 24
Mar 25
Mar 26
Sep 26
Shareholders' equity · YoY (vs a year ago)
—+14%+17%+10%—
Shareholders' equityBorrowingsCashLine = trend
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| Shareholders' equity | 23,408 | 26,706 | 31,193 | 34,432 | 35,396 |
| Long-term borrowings | 0.0 | 0.0 | 12.0 | 117 | 131 |
| Short-term borrowings | 520 | 247 | 80.1 | 141 | 136 |
| Total borrowings | 520 | 247 | 92.1 | 258 | 267 |
| Current liabilities | 5,033 | 5,246 | 5,484 | 7,014 | 6,977 |
| Fixed assets (PPE) | 4,991 | 5,069 | 5,262 | 6,040 | 6,555 |
| Inventories | 5,156 | 5,238 | 5,642 | 6,597 | 6,778 |
| Trade receivables | 4,057 | 4,771 | 5,506 | 5,620 | 6,000 |
| Cash & equivalents | 628 | 640 | 589 | 1,018 | 1,659 |
| Current assets | 16,805 | 19,392 | 23,249 | 24,146 | 25,061 |
| Total assets | 29,463 | 32,718 | 37,387 | 42,496 | 43,434 |
| Debt / equity | 0.02 | 0.01 | 0.00 | 0.01 | 0.01 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
FY22
FY23
FY24
FY25
FY26
Operations · YoY (vs a year ago)
—-2.7%+28%+21%-21%
OperationsInvestingFinancingLine = trend
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 3,326 | 3,238 | 4,134 | 5,005 | 3,940 |
| Cash from investing | -1,872 | -2,389 | -2,988 | -3,691 | -2,326 |
| Cash from financing | -1,600 | -958 | -1,200 | -1,293 | -1,234 |
| Spent on fixed assets | -544 | -841 | -1,098 | -1,162 | -1,599 |
| Free cash flow | 2,782 | 2,397 | 3,036 | 3,843 | 2,341 |
| Net cash flow | -146 | -109 | -54.6 | 21.1 | 380 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Promoter & groupPublic
Latest (30 Sep 2026)
29.2%promoter
- Promoter & group
- 29.21%
- Public (FIIs, mutual funds, retail…)
- 70.79%
- Promoter change, last quarter
- 0.00 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Dividend - Rs 13 Per Share
- Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per Share
- Dividend - Rs 13 Per Share
- Dividend - Rs 8.50 Per Share
- Dividend - Rs 5 Per Share
- Annual General Meeting/Dividend - Rs 5 Per Share
- Annual General Meeting
- Interim Dividend - Rs 3 Per Share Special Dividend - Re 1 Per Share
Board meetings
- CIPLA LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial resu…
- Cipla limited has informed the Exchange about Board Meeting to be held on 27th October, 2026 to inter-alia consider and approve the Unaudited Financi…
- CIPLA LIMITED has informed the Exchange about Board Meeting to be held on 23-Jul-2026 to inter-alia consider and approve the Unaudited Financial resu…
- the unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June, 2026.In terms of the Company's Code of Co…
- the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.
Filings with NSE
- Copy of Newspaper Publication
- Change in Management
- Copy of Newspaper Publication
- Analysts/Institutional Investor Meet/Con. Call Updates
- ESOP/ESOS/ESPS
- Copy of Newspaper Publication
- Analysts/Institutional Investor Meet/Con. Call Updates
Latest news
CIPLA Outlook for the WeekEquitypandit · 8 Nov, 1:30 pmCipla Share Price Falls Over 3% After Q1 FY27 Results Disappoint Investors; Profit Drops 39%India Infoline · 23 Jul, 12:30 pmCipla stock up 4% to emerge as top Nifty gainer; Citi sees series of near-term positive US triggersMoneycontrol.com · 22 Jun, 12:30 pmWhy Cipla Share Price is RisingEquitymaster · 24 Jul, 12:30 pmCipla shares soars 8% as India business delivers double-digit growth; what analysts saidUpstox · 14 May, 12:30 pmCipla shares drop 2% after US FDA designates its Greece facility as OAIBusiness Standard · 23 Feb, 1:30 pmCipla Share Price Update: Sector Benchmark and ValuationUnivest · 21 Sep, 12:30 pmCipla Q4 Results 2026: Share Price Target & Dividend DetailsLiquide Blog · 14 May, 12:30 pmAbout
About Cipla Limited
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Cipla Limited
- NSE symbol
- CIPLA
- BSE scrip code
- 500087
- ISIN
- INE059A01026
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 8 Feb 1995
- Face value
- ₹2 per share
- Market lot
- 1 share
- Shares issued
- 80.79 crore
- Index
- NIFTY 50, NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Other
- Managing director / CEO
- Achin Gupta
- Chair
- Y. K. Hamied
- Headquarters
- Mumbai, Maharashtra, India
- Registered address
- Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013
- Founded
- 1935
- Employees
- 47,496
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- cipla.com
Peers
Other Healthcare stocks
-
DIVISLABDivi's Laboratories
₹11,485.00
+1.04%
-
ALKEMAlkem Laboratories
₹5,302.00
-2.68%
-
GRANULESGranules India
₹840.50
+5.16%
-
SUNPHARMASun Pharmaceutical Industries
₹1,885.00
-0.91%
-
LAURUSLABSLaurus Labs
₹2,400.00
-1.19%
-
AUROPHARMAAurobindo Pharma
₹1,807.20
-1.11%
-
ACUTAASAcutaas Chemicals
₹3,996.10
+2.02%
-
APOLLOHOSPApollo Hospitals Enterprise
₹8,515.00
-1.03%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.